Gino Santini

Our mission is to improve peoples health and quality of life by offering caregivers and healthcare professionals therapeutic solutions according to the highest standards of quality and safety, in the name of innovation. Alfasigma is one of the leading Italian pharmaceutical companies, operating in over 100 countries worldwide with approximately 4,000 employees dedicated to research, development, production, and distribution. With more than 70 years of history, the Company has a longstanding track record in developing innovative therapeutic indications to meet the new needs of patients while renewing and consolidating its existing products. Alfasigma has a strong focus in gastroenterology and worldwide has products also in vascular, metabolic areas and in nutraceuticals and medical foods. As part of its strategy to expand its specialty care portfolio, Alfasigma strengthened its international presence with targeted acquisitions in US and Europe in 2023. Alfasigma’s historical headquarters are located in Bologna, with another office in Milan. It has production sites in Italy, in Pomezia (RM), Alanno (PE), Sermoneta (LT) and Trezzano Rosa (MI), and abroad in Tortosa, Spain and in Shreveport (Louisiana) in the United States. Its R&D laboratories are in Pomezia and in the Parco Scientifico Tecnologico Kilometro Rosso in Bergamo. Read here our social media netiquette: https://it.alfasigma.com/informative-privacy/netiquettesocialnetwork/

Collegium Pharmaceutical is building a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a portfolio of differentiated medications to treat serious medical conditions.

Horizon Therapeutics is now part of Amgen. The Horizon LinkedIn page is no longer active or monitored.

Our mission is to improve peoples health and quality of life by offering caregivers and healthcare professionals therapeutic solutions according to the highest standards of quality and safety, in the name of innovation. Alfasigma is one of the leading Italian pharmaceutical companies, operating in over 100 countries worldwide with approximately 4,000 employees dedicated to research, development, production, and distribution. With more than 70 years of history, the Company has a longstanding track record in developing innovative therapeutic indications to meet the new needs of patients while renewing and consolidating its existing products. Alfasigma has a strong focus in gastroenterology and worldwide has products also in vascular, metabolic areas and in nutraceuticals and medical foods. As part of its strategy to expand its specialty care portfolio, Alfasigma strengthened its international presence with targeted acquisitions in US and Europe in 2023. Alfasigma’s historical headquarters are located in Bologna, with another office in Milan. It has production sites in Italy, in Pomezia (RM), Alanno (PE), Sermoneta (LT) and Trezzano Rosa (MI), and abroad in Tortosa, Spain and in Shreveport (Louisiana) in the United States. Its R&D laboratories are in Pomezia and in the Parco Scientifico Tecnologico Kilometro Rosso in Bergamo. Read here our social media netiquette: https://it.alfasigma.com/informative-privacy/netiquettesocialnetwork/

We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.

We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.